Started in 2018, the FDA’s “Real-Time Oncology Review (ROTR)” project gives sponsors a head start on the application review process and poses additional challenges. The ROTR helps sponsors plan around anticipated FDA results immediately to begin preparing their full submission package […]
xCures Releases xDECIDE Platform to Personalize Cancer Care Using RWD
Released earlier this month, the xDECIDE platform helps doctors choose the optimal treatment strategy for cancer patients, according to a press release from xCures. The consolidated online platform uses real-world data (RWD), expert recommendations, and an advanced learning network to provide a […]
Are Mammograms After 75 Worth It?
Uncertainty is building regarding the value of mammograms for breast cancer screening after 75 years of age according to a study published in the journal Annals of Internal Medicine. The harms of overdiagnosis may outweigh the human and economic benefits of the relatively small number of breast […]
[JAMA Article] New Oncology Drugs Command High Price Tags Despite Lack of Improved Survival
In an article published in JAMA Internal Medicine, researchers assessed the costs of 44 new oncology drugs. Surprisingly, they found that an increasing number of patients were receiving drugs without clear overall survival data. “The investigators suggested that the increased spending on cancer […]
New Report Considers Use of Oncology RWE in Successful Submissions to the FDA
In a recent article published in Clinical Cancer Research, investigators analyzed successful submissions of oncology drugs to the Food and Drug Administration (FDA) that utilized real world evidence (RWE). The researchers identified elements criticized by the FDA, including confounding factors, and […]
Takeda Partners With Point32Health to Offer Value-Based Oncology Program in US
Takeda has partnered with Point32Health in a new value-based oncology program. Alunbrig, used in non-small cell lung cancer, is the first drug offered through the pilot project; if successful, Takeda promises to expand the program. Takeda Oncology’s Dion Warren remarks, “We need to learn through […]
Merck’s Keytruda Expected to Hit $17 Billion Yearly Revenue
Merck’s Keytruda continues to generate billion-dollar sales. The oncology drug reached $4.5 billion of sales in the third quarter, making a cornerstone of Merck’s offerings. Its list price is approximately $175,000 per year. “Keytruda is close to becoming the highest-selling drug in the world and […]
EQRx Partners With Two Payers to Reduce Drug Costs, Seeks Chinese Approval of Low Cost Oncology Drugs
EQRx has formed partnerships with two healthcare insurance companies to reach its ambitious goal of reducing drug costs. The company has also sought approval for two cost-effective oncology drugs used in lung cancer in China. Will these moves be enough? “EQRx — the buzzy biotech company with a […]
xCures Seeks to Improve Patient Outcomes Using Targeted Oncology RWD
xCures aims to improve the outcomes of patients with cancer using real world data (RWD) tools. Quickly identifying relevant patient populations is a critical first step in understanding market access challenges and a drug’s efficacy in the real world, among other applications. xCures has created an […]
[Podcast] Merck Marketing Expert Discusses AI in Oncology Care
In a recent episode of Life Science Marketing Radio, Chris Conner interviewed Hemal Somaiya, Global Brand Lead for Oncology at Merck KGAa. Somaiya discussed how artificial intelligence (AI) can impact digital marketing in healthcare. “If you are curious about how AI can be used to target […]
